Value reimagined: Unlocking ROI and efficiency in drug development

As costs climb and timelines tighten, the traditional clinical development outsourcing model is showing its age. Fragmented handoffs between contract development and manufacturing organizations (CDMOs), contract research organizations (CROs), and clinical supply vendors often create delays, inefficiencies, and missed opportunities.

A new study by the Tufts Center for the Study of Drug Development offers fresh insight by quantifying the financial and operational impact of a fully integrated development model.

The result? Up to 113x ROI and $62.9 million in projected value for Phase III oncology programs alone.

Discover how aligning manufacturing, clinical research, supply services, and labs can reduces complexity, streamlines execution, and unlocks significant ROI.